Inhibikase Therapeutics 8-K: Executive Comp & Officer Changes

TL;DR

**Inhibikase Therapeutics just filed an 8-K about executive pay and potential leadership changes.**

AI Summary

Inhibikase Therapeutics, Inc. filed an 8-K on January 16, 2024, to report changes in its executive compensation arrangements and potentially the departure or election of directors or officers. This filing, under Items 5.02 and 9.01, indicates that the company is making adjustments to how it compensates its leadership, which could reflect strategic shifts or efforts to retain key talent. For investors, this matters because changes in executive compensation can signal confidence in future performance or, conversely, attempts to stabilize leadership during challenging times, directly impacting the company's operational stability and long-term value.

Why It Matters

Changes in executive compensation and officer roles can signal strategic shifts or efforts to retain key talent, directly impacting the company's operational stability and future performance.

Risk Assessment

Risk Level: medium — Changes in executive compensation and officer roles can introduce uncertainty regarding leadership stability and future strategic direction, posing a moderate risk to investors.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details on the compensatory arrangements and any changes in directors or officers, as these could impact future operational strategy and financial performance.

Key Numbers

• 001-39676 — Commission File Number (identifies the company's filings with the SEC)
• 2024-01-16 — Date of Report (the earliest event reported in the filing)
• 678-392-3419 — Registrant's Telephone Number (contact information for Inhibikase Therapeutics, Inc.)
• $0.001 — par value per share (par value of Inhibikase Therapeutics, Inc. Common Stock)

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Inhibikase Therapeutics, Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Inhibikase Therapeutics, Inc. Common Stock is registered
• IKT (company) — trading symbol for Inhibikase Therapeutics, Inc.

Forward-Looking Statements

• Inhibikase Therapeutics will announce specific details regarding executive compensation changes or new officer appointments. (Inhibikase Therapeutics, Inc.) — medium confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark

Filing Documents

• d125920d8k.htm (8-K) — 28KB
• d125920dex991.htm (EX-99.1) — 12KB
• g125920g0116022524742.jpg (GRAPHIC) — 3KB
• 0001193125-24-008593.txt ( ) — 173KB
• ikt-20240116.xsd (EX-101.SCH) — 3KB
• ikt-20240116_lab.xml (EX-101.LAB) — 18KB
• ikt-20240116_pre.xml (EX-101.PRE) — 11KB
• d125920d8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 16, 2024, Joseph Frattaroli provided notice to the Board of Directors (the "Board") of Inhibikase Therapeutics, Inc. (the "Company") of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024. Mr. Frattaroli's planned retirement as Chief Financial Officer is not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices. In connection with Mr. Frattaroli's planned retirement, the Compensation Committee of the Board has extended the exercise period of each of Mr. Frattaroli's vested stock options with time based vesting until the original expiration date of each of such stock options. The Board will appoint Garth Lees-Rolfe to serve as Chief Financial Officer of the Company upon Mr. Frattaroli's retirement and until the earliest of his removal, termination, or resignation from such office. Mr. Lees-Rolfe, age 39, has served as the Vice President of Finance at the Company since November 2022. Mr. Lees-Rolfe previously served as the Vice-President, Finance for F-Star, Inc., a publicly traded global clinical-stage biotech company from December 2021 to November 2022. Prior to that, Mr. Lees-Rolfe worked for 16 years in public practice, most of which was with Ernst & Young, most recently as Senior Manager from 2016 to 2021. Mr. Lees-Rolfe earned a Bachelor of Business from the Queensland University of Technology and a Graduate Certificate in Applied Finance from Kaplan Professional. He is a licensed Certified Public Accountant in the state of Massachusetts and a licensed Chartered Accountant of Australia and New Zealand. The terms of Mr. Lees-Rolfe's compensation as Chief Financial Officer have yet to be determined. The Company will file an amendment to th

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Number Description 99.1 Press Release dated January 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR